Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Kontsevaya I, Werngren J, Holicka Y, Klaos K, Tran A, Nikolayevskyy V.

Eur J Clin Microbiol Infect Dis. 2019 Oct 30. doi: 10.1007/s10096-019-03723-8. [Epub ahead of print] Review.

PMID:
31667670
2.

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.

Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.

Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068.

PMID:
30561569
3.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

4.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
5.

An unbiased attitude is vital to exploring the Beijing genotype of Mycobacterium tuberculosis.

Zheng Q, Werngren J.

Tuberculosis (Edinb). 2018 Jul;111:193-197. doi: 10.1016/j.tube.2018.06.014. Epub 2018 Jun 30.

6.

Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.

Willby MJ, Wijkander M, Havumaki J, Johnson K, Werngren J, Hoffner S, Denkinger CM, Posey JE.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01871-17. doi: 10.1128/AAC.01871-17. Print 2018 Jan.

7.

Reduced susceptibility of clinical strains of Mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages.

Idh J, Andersson B, Lerm M, Raffetseder J, Eklund D, Woksepp H, Werngren J, Mansjö M, Sundqvist T, Stendahl O, Schön T.

PLoS One. 2017 Jul 13;12(7):e0181221. doi: 10.1371/journal.pone.0181221. eCollection 2017.

8.

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015.

Mansjo M, Werngren J, Hoffner S.

Int J Mycobacteriol. 2017 Apr-Jun;6(2):156-161. doi: 10.4103/ijmy.ijmy_23_17.

9.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.

Anthony RM, Cynamon M, Hoffner S, Werngren J, den Hertog AL, van Soolingen D.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00258-17. doi: 10.1128/AAC.00258-17. Print 2017 Jun. No abstract available.

10.

Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?

Werngren J, Alm E, Mansjö M.

J Clin Microbiol. 2017 Jun;55(6):1920-1927. doi: 10.1128/JCM.02532-16. Epub 2017 Apr 12.

11.

New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens.

Anthony RM, den Hertog A, Mansjö M, Werngren J.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S71-S72. doi: 10.1016/j.ijmyco.2016.08.009. Epub 2016 Sep 20.

12.

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Li D, Hu Y, Werngren J, Mansjö M, Zheng X, Drobniewski F, Hoffner S, Xu B.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5159-66. doi: 10.1128/AAC.02687-15. Print 2016 Sep.

13.

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.

Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug.

14.

Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis.

Gustafsson TN, Osman H, Werngren J, Hoffner S, Engman L, Holmgren A.

Biochim Biophys Acta. 2016 Jun;1860(6):1265-71. doi: 10.1016/j.bbagen.2016.03.013. Epub 2016 Mar 10.

PMID:
26971857
15.

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.

Hu Y, Zhao Q, Werngren J, Hoffner S, Diwan VK, Xu B.

BMC Infect Dis. 2016 Jan 7;16:4. doi: 10.1186/s12879-015-1331-z.

16.

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T.

Clin Microbiol Infect. 2015 Feb;21(2):148.e5-7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29.

17.

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.

Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopeć E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM.

mBio. 2014 Oct 21;5(5):e01819-14. doi: 10.1128/mBio.01819-14.

18.

A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting.

Wedajo W, Schön T, Bedru A, Kiros T, Hailu E, Mebrahtu T, Yamuah L, Ängeby K, Werngren J, Onyebujoh P, Dagne K, Aseffa A.

BMC Res Notes. 2014 Aug 10;7:512. doi: 10.1186/1756-0500-7-512.

19.

Evaluation of a microcolony growth monitoring method for the rapid determination of ethambutol resistance in Mycobacterium tuberculosis.

den Hertog AL, Menting S, Smienk ET, Werngren J, Hoffner S, Anthony RM.

BMC Infect Dis. 2014 Jul 10;14:380. doi: 10.1186/1471-2334-14-380.

20.

Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis.

Gonzalo X, Drobniewski F, Hoffner S, Werngren J.

J Antimicrob Chemother. 2014 Nov;69(11):3001-5. doi: 10.1093/jac/dku230. Epub 2014 Jun 23.

PMID:
24962032
21.

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.

Hameed P S, Patil V, Solapure S, Sharma U, Madhavapeddi P, Raichurkar A, Chinnapattu M, Manjrekar P, Shanbhag G, Puttur J, Shinde V, Menasinakai S, Rudrapatana S, Achar V, Awasthy D, Nandishaiah R, Humnabadkar V, Ghosh A, Narayan C, Ramya VK, Kaur P, Sharma S, Werngren J, Hoffner S, Panduga V, Kumar CN, Reddy J, Kumar K N M, Ganguly S, Bharath S, Bheemarao U, Mukherjee K, Arora U, Gaonkar S, Coulson M, Waterson D, Sambandamurthy VK, de Sousa SM.

J Med Chem. 2014 Jun 12;57(11):4889-905. doi: 10.1021/jm500432n. Epub 2014 May 23.

PMID:
24809953
22.

In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.

Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy VK, Rodrigues C, Hoffner S.

Antimicrob Agents Chemother. 2014 Jul;58(7):4222-3. doi: 10.1128/AAC.02718-14. Epub 2014 Apr 28.

23.

Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.

P SH, Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, R M, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V.

Antimicrob Agents Chemother. 2014;58(1):61-70. doi: 10.1128/AAC.01751-13. Epub 2013 Oct 14. Erratum in: Antimicrob Agents Chemother. 2014 Aug;58(8):4993-4.

24.

Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.

Hoffner S, Angeby K, Sturegård E, Jönsson B, Johansson A, Sellin M, Werngren J.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1486-90. doi: 10.5588/ijtld.13.0195.

PMID:
24125455
25.

Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods.

Folkvardsen DB, Thomsen VØ, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E.

J Clin Microbiol. 2013 Dec;51(12):4220-2. doi: 10.1128/JCM.01602-13. Epub 2013 Sep 25.

26.

Mycobacterium tuberculosis Beijing type mutation frequency.

Werngren J.

Emerg Infect Dis. 2013 Mar;19(3):522. No abstract available.

27.

Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis?

Folkvardsen DB, Svensson E, Thomsen VØ, Rasmussen EM, Bang D, Werngren J, Hoffner S, Hillemann D, Rigouts L.

J Clin Microbiol. 2013 May;51(5):1596-9. doi: 10.1128/JCM.00472-13. Epub 2013 Feb 27.

28.

Resistance to first-line anti-TB drugs is associated with reduced nitric oxide susceptibility in Mycobacterium tuberculosis.

Idh J, Mekonnen M, Abate E, Wedajo W, Werngren J, Ängeby K, Lerm M, Elias D, Sundqvist T, Aseffa A, Stendahl O, Schön T.

PLoS One. 2012;7(6):e39891. doi: 10.1371/journal.pone.0039891. Epub 2012 Jun 29.

29.

Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis.

Warrier T, Tropis M, Werngren J, Diehl A, Gengenbacher M, Schlegel B, Schade M, Oschkinat H, Daffe M, Hoffner S, Eddine AN, Kaufmann SH.

Antimicrob Agents Chemother. 2012 Apr;56(4):1735-43. doi: 10.1128/AAC.05742-11. Epub 2012 Jan 30.

30.

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1253-7. doi: 10.1128/AAC.05894-11. Epub 2011 Dec 27.

31.

Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment.

Mariam SH, Werngren J, Aronsson J, Hoffner S, Andersson DI.

PLoS One. 2011;6(6):e21147. doi: 10.1371/journal.pone.0021147. Epub 2011 Jun 16.

32.

Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis medicinal herb inhibits drug resistant strains of Mycobacterium tuberculosis in vitro.

Lakshmanan D, Werngren J, Jose L, Suja KP, Nair MS, Varma RL, Mundayoor S, Hoffner S, Kumar RA.

Fitoterapia. 2011 Jul;82(5):757-61. doi: 10.1016/j.fitote.2011.03.006. Epub 2011 Apr 1.

PMID:
21459133
33.

Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.

Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P.

J Antimicrob Chemother. 2011 Jun;66(6):1247-54. doi: 10.1093/jac/dkr109. Epub 2011 Mar 21.

PMID:
21427106
34.

Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.

Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, Juréen P, Hoffner S, Del Portillo P, Morcillo N, Palomino JC.

J Antimicrob Chemother. 2011 Apr;66(4):827-33. doi: 10.1093/jac/dkq527. Epub 2011 Jan 19.

PMID:
21393176
35.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23.

PMID:
20332195
36.

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T.

J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17.

37.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.

PMID:
19633001
38.

Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Juréen P, Werngren J, Toro JC, Hoffner S.

Antimicrob Agents Chemother. 2008 May;52(5):1852-4. doi: 10.1128/AAC.00110-08. Epub 2008 Mar 3.

39.

Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.

Huitric E, Werngren J, Juréen P, Hoffner S.

Antimicrob Agents Chemother. 2006 Aug;50(8):2860-2.

40.
41.

Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.

Juréen P, Werngren J, Hoffner SE.

Tuberculosis (Edinb). 2004;84(5):311-6.

PMID:
15207806
42.

Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis.

Angeby KA, Werngren J, Toro JC, Hedström G, Petrini B, Hoffner SE.

Clin Microbiol Infect. 2003 Nov;9(11):1148-52.

44.

Antimicrobial susceptibility of Mycobacterium marinum determined by E-test and agar dilution.

Werngren J, Olsson-Liljequist B, Gezelius L, Hoffner SE.

Scand J Infect Dis. 2001;33(8):585-8.

PMID:
11525351

Supplemental Content

Loading ...
Support Center